Ar­rakis Ther­a­peu­tics re­duces head­count by 20%

Ar­rakis Ther­a­peu­tics has pri­or­i­tized its pipeline and re­duced its head­count by about 20% this week, the biotech’s CEO said in a state­ment to End­points News …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.